Evidence map›Paper›PMID 36371187›Full record

ArticleBMC cancer2022

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.

Tao Yang, Rui Xu, Junhao You, Fang Li, Bing Yan, Jia-Nan Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Observational
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tao Yang *Department of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, 572013, Hainan, China.
Rui Xu *Department of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, 572013, Hainan, China.
Junhao YouDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, 572013, Hainan, China.
Fang LiDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, 572013, Hainan, China.
Bing YanDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, 572013, Hainan, China. y_bing41@163.com.
Jia-Nan ChengInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China. 982263928@qq.com.

Funding

National Nature Science Foundation of China No.82003006National Nature Science Foundation of China No.82102878Nature Science Foundation of Hainan Province No.821QN384
6 · The paper itself

Abstract

introductionGastric cancer is the most fifth common tumor worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis and clinical characteristics in gastric cancer. Nevertheless, the biology of HER2-low expression has not reported in gastric cancer. MATERIALS AND

methodsA total of 157 patients with early-stage gastric cancer were retrospectively analyzed. The associations between HER-2 low expression and clinical characteristics were analyzed by Chi-square test. And the prognostic value of HER-2 low expression and clinical characteristics in disease-free survival (DFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression analysis.

resultsOf 157 patients with early-stage gastric cancer, 31.8% had HER2-low tumors and 50.3% had HER2-negative tumors. HER2-low expression was associated with age, histological differentiation, tumor location and Ki-67 index. However, HER2-low expression was not associated with DFS or OS in early-stage gastric cancer.

conclusionHER2-low expression might result in distinct biology, but it was not an independent prognostic factor of DFS or OS in early-stage gastric cancer.

Indexed as

Stomach NeoplasmsDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesHumansPrognosisRetrospective StudiesErb-b2 Receptor Tyrosine KinasesClinical characteristicsGastric cancerHER-2Prognosis

Identifiers

PMID36371187
PMCPMC9652852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.